Abstract: A method for estimating fault location in an electrical power line system (PLS) is provided. The method includes receiving an observed signal caused by a real fault in the PLS. The observed signal is measured at a real observation point in the PLS. The real fault has occurred at one of two or more real locations in the PLS; accessing a library representing model signals between model guessed fault locations and a model observation point in a network model of the PLS; selecting a model GFL by: (i) calculating metrics for the model signals by processing the model signals with the observed signal, and/or (ii) selecting the model GFL corresponding to a highest calculated metric; estimating a fault location of real locations in the PLS based on a corresponding location of the selected model GFL; and sending the estimated fault location to an external management system.

Abstract: The invention relates to vaccine compositions for inducing an immune response to a coronavirus in a subject, and uses thereof. In particular, the vaccine comprises of a chimeric or fusion protein comprising a) a N-terminal secretion signal peptide; b) an amino acid sequence of the receptor binding domain (RBD) of a spike protein of a coronavirus; and c) a C-terminal domain comprising a transmembrane region and a cytoplasmic region. In a preferred embodiment, the signal peptide, RBD, transmembrane region, and cytoplasmic region are derived from SARS-CoV-2, and that the vaccine composition is formulated as a lipid nanoparticle (LNP).

Abstract: Stability to long term charge and discharge cycles is the most formidable challenge for Lithium-Sulfur batteries. Therefore, a more holistic design of a durable cathode with minimal polysulfide escape to mitigate the corrosion of the lithium anode is required. A saccharide-based binder system—the monosaccharide (glucose) component, on account of being a strong reducing agent has a unique capacity for the regulation of polysulfide thereby dramatically enhancing the functionality of a polysaccharide (carboxymethyl cellulose) binder system. The two-component binder system promotes the formation of viscoelastic filaments during casting which endows sulfur cathode a desired web-like microstructure. The combination of these effects leads to 97% sulfur utilisation with an ultra-long cycle life of 1000 cycles (9 months) and a high capacity retention (around 700 mAhg?1 after 1000 cycles). A pouch cell prototype with a capacity of 1200 mAhg?1 demonstrates a promising transition from laboratory to manufacturing options.

Abstract: A system including: a distance sensor system located/oriented/configured to measure a deformation of a geomaterial portion due to compaction of the geomaterial portion; and an electronic processing system configured to: receive signals from the distance sensor system representing the measured deformation, and automatically generate an estimate/measure of a geomaterial layer property of the geomaterial portion based on: the measured deformation; and a pre-defined relationship/model that associates deformation values with geomaterial layer property values (e.g., density values, stiffness values, modulus values, energy values, or layer thicknesses during compaction).

Abstract: This invention relates to polypeptides, including variants of interleukin-38 (IL-38), and related therapeutics and compositions. The invention also relates to the use of the polypeptides and compositions in methods of treating inflammatory diseases or conditions. The present invention provides a monomeric polypeptide comprising an amino acid sequence of an IL-38 monomer, the amino acid sequence having a mutation or modification for preventing the peptide from forming a homodimer and favouring the formation of a stable monomer.

Abstract: This invention relates to drug delivery and in particular to the delivery of biologically active agents in the form of dry powders for inhalation. The invention also relates to methods for preparing such dry powder formulations and methods for their use.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

Abstract: This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV.

Abstract: The invention relates generally to a method of detecting and/or analysing target polymers, especially target polynucleotides, using a biological pore. The invention also relates to a novel system for carrying out the method. The method has many uses. In particular, the method may be used for diagnosis, detection of polymorphisms and V(D)J repertoire analysis.

Abstract: The present invention is directed to lipid nanoparticles, formulations containing lipid nanoparticles and methods of treating diseases or conditions with said lipid nanoparticles and formulations thereof. A lipid nanoparticle comprising (a) an active agent; (b) a cationic and/or ionisable lipid comprising from about 40 mol % to about 60 mol % of the total lipid present in the nanoparticle; (c) a phospholipid comprising from about 5 mol % to about 20 mol % of the total lipid present in the nanoparticle; (d) a structural lipid comprising from about 30 mol % to about 50 mol % of the total lipid present in the nanoparticle; (e) a PEGylated lipid comprising from about 0.05 mol % to less than 0.5 mol % of the total lipid present in the nanoparticle.

Abstract: Disclosed herein is a phenolic-graphene oxide composition comprising phenolic-graphene oxide having a carbon to oxygen (C:O) ratio of 2.1 or greater and 5 or less.

Abstract: A method of screening candidate agents for their ability to modulate RAGE activity where such RAGE activity is induced by an active co-located GPCR, the method comprising the steps of: contacting a RAGE polypeptide with a GPCR polypeptide in the presence of a candidate agent where the GPCR polypeptide is constitutively active and/or is activated by addition of an agonist, partial agonist or allosteric modulator of that GPCR; and detecting whether the candidate agent is a modulator of RAGE ligand-independent activation of RAGE by activated co-located GPCR by detecting an effect indicative of modulation of RAGE activation by the presence of the candidate agent and/or by detecting RAGE-dependent signalling that is modulated by the presence of the candidate agent.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: Disclosed herein is a method for co-pyrolysis of a polyolefin and a rubber containing material comprising: operating at least a pyrolysis stage of a pyrolysis reactor at an operating temperature at or above the temperature at which pyrolysis of both the polyolefin and the rubber containing material commences and up to about 600° C. under a substantially inert atmosphere; feeding a mixture comprising the polyolefin and the rubber containing material into the pyrolysis reactor; co-pyrolysing the mixture in the pyrolysis reactor to produce a pyrolysis gas comprising volatile pyrolysis products of the polyolefin and the rubber, wherein the volatile pyrolysis product of the olefin comprises at least a short chain olefin and the volatile product of the rubber comprises at least a diene; and facilitating a gas phase reaction between the short chain olefin and the diene to produce a volatile gas comprising single-ring aromatic hydrocarbons.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: A method and system for reconstructing magnetic resonance (MR) images, the method including the steps of: receiving an under-sampled MR image, the under-sampled MR image being transformed from under-sampled k-spaced data; classifying intensity of each pixel in the under-sampled MR image to one of a plurality of predetermined quantized values of intensity by using a neural network; and generating a reconstructed MR image based on the classified quantized value of the intensity for each pixel in the under-sampled MR image.

Abstract: The present invention relates to chimeric and fusion proteins and their compositions, and the use of such proteins and compositions in the prevention and/or treatment diseases or conditions requiring plasminogen supplementation. In one aspect, the invention provides a chimeric or fusion protein comprising plasminogen and an Fc region of an antibody.

Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

Abstract: The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.